Dose-response relationship in patients who received transarterial radioembolization with Y-90 resin microspheres for hepatocellular carcinoma.

IF 1.3 4区医学 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Nuclear Medicine Communications Pub Date : 2025-10-01 DOI:10.1097/MNM.0000000000002058

Cigdem Soydal, Ecenur Dursun Avci, Irem Mesci, Emre Can Celebioglu, Digdem Kuru Oz, Nuriye Ozlem Kucuk

{"title":"Dose-response relationship in patients who received transarterial radioembolization with Y-90 resin microspheres for hepatocellular carcinoma.","authors":"Cigdem Soydal, Ecenur Dursun Avci, Irem Mesci, Emre Can Celebioglu, Digdem Kuru Oz, Nuriye Ozlem Kucuk","doi":"10.1097/MNM.0000000000002058","DOIUrl":null,"url":null,"abstract":"Objective: The aim of this study is to analyze the dose-response relationship in hepatocellular carcinoma (HCC) patients who received transarterial radioembolization (TARE) with Y-90 resin microspheres.Methods: Patients who received TARE with Y-90 resin microspheres using multicompartment dosimetry between February 2020 and December 2024 were included in the analysis. A total of 46 lesions from 21 patients were included in the dose-response analysis. Multicompartment dosimetry was performed for all lesions in the perfused area. Additionally, the mean tumor absorbed dose (TAD), whole-liver absorbed dose, and perfused-liver absorbed dose were calculated.Results: All the patients received Y-90 resin microspheres with a lobar or segmental approach. Median tumor volume was calculated as 9.4 cm³ (min-max: 1-1674). During the third-month evaluation, 21 lesions were responders. In the receiver operating characteristic analysis, a 104 Gy cutoff for mean TAD [AUC: 0.693, 95% confidence interval (CI): 0.532-0.853, P = 0.018] was calculated for response, with 76% sensitivity and 64% specificity. For the prediction of complete response, we found a 159 Gy cutoff for mean TAD (AUC: 0.776, 95% CI: 0.598-0.953, P = 0.002), with 70% sensitivity and 79% specificity.Conclusion: We demonstrated a strong relationship between absorbed tumor dose and treatment response in HCC patients who received TARE with Y-90 resin microspheres. Delivery of approximately 100 Gy mean absorbed dose to the tumor is needed to achieve a response. Increasing the TAD to ~160 Gy would be expected to result in a complete response.","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":""},"PeriodicalIF":1.3000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nuclear Medicine Communications","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/MNM.0000000000002058","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: The aim of this study is to analyze the dose-response relationship in hepatocellular carcinoma (HCC) patients who received transarterial radioembolization (TARE) with Y-90 resin microspheres.

Methods: Patients who received TARE with Y-90 resin microspheres using multicompartment dosimetry between February 2020 and December 2024 were included in the analysis. A total of 46 lesions from 21 patients were included in the dose-response analysis. Multicompartment dosimetry was performed for all lesions in the perfused area. Additionally, the mean tumor absorbed dose (TAD), whole-liver absorbed dose, and perfused-liver absorbed dose were calculated.

Results: All the patients received Y-90 resin microspheres with a lobar or segmental approach. Median tumor volume was calculated as 9.4 cm³ (min-max: 1-1674). During the third-month evaluation, 21 lesions were responders. In the receiver operating characteristic analysis, a 104 Gy cutoff for mean TAD [AUC: 0.693, 95% confidence interval (CI): 0.532-0.853, P = 0.018] was calculated for response, with 76% sensitivity and 64% specificity. For the prediction of complete response, we found a 159 Gy cutoff for mean TAD (AUC: 0.776, 95% CI: 0.598-0.953, P = 0.002), with 70% sensitivity and 79% specificity.

Conclusion: We demonstrated a strong relationship between absorbed tumor dose and treatment response in HCC patients who received TARE with Y-90 resin microspheres. Delivery of approximately 100 Gy mean absorbed dose to the tumor is needed to achieve a response. Increasing the TAD to ~160 Gy would be expected to result in a complete response.

查看原文本刊更多论文

经动脉放射栓塞Y-90树脂微球治疗肝癌患者的剂量-反应关系。

目的：分析Y-90树脂微球经动脉放射栓塞治疗肝细胞癌（HCC）患者的剂量-反应关系。方法：纳入2020年2月至2024年12月间采用多室剂量法接受Y-90树脂微球TARE治疗的患者。来自21名患者的46个病变被纳入剂量-反应分析。对灌注区所有病变进行多室剂量测定。计算肿瘤平均吸收剂量（TAD）、全肝吸收剂量、灌注肝吸收剂量。结果：所有患者均采用大叶或节段入路植入Y-90树脂微球。计算肿瘤中位体积为9.4 cm³（最小-最大：1-1674）。在第三个月的评估中，21个病灶有反应。在受试者工作特征分析中，计算平均TAD的104 Gy临界值[AUC: 0.693, 95%可信区间（CI）： 0.532-0.853, P = 0.018]，敏感性为76%，特异性为64%。对于完全缓解的预测，我们发现平均TAD的截断值为159 Gy (AUC: 0.776, 95% CI: 0.598-0.953, P = 0.002)，敏感性为70%，特异性为79%。结论：我们证明了在接受Y-90树脂微球TARE治疗的HCC患者中，肿瘤吸收剂量与治疗反应之间存在很强的关系。需要向肿瘤提供约100戈瑞的平均吸收剂量才能达到反应。将TAD增加到~160 Gy，预计会产生完全响应。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nuclear Medicine Communications 医学-核医学

CiteScore

2.20

自引率

6.70%

发文量

212

审稿时长

3-8 weeks

期刊介绍： Nuclear Medicine Communications, the official journal of the British Nuclear Medicine Society, is a rapid communications journal covering nuclear medicine and molecular imaging with radionuclides, and the basic supporting sciences. As well as clinical research and commentary, manuscripts describing research on preclinical and basic sciences (radiochemistry, radiopharmacy, radiobiology, radiopharmacology, medical physics, computing and engineering, and technical and nursing professions involved in delivering nuclear medicine services) are welcomed, as the journal is intended to be of interest internationally to all members of the many medical and non-medical disciplines involved in nuclear medicine. In addition to papers reporting original studies, frankly written editorials and topical reviews are a regular feature of the journal.